Novartis AG is 7.3x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($283.13 B vs $38.62 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ALNY | NVS |
|---|---|---|
| Market cap | $38.62 B | $283.13 B |
| US-listed rank | #396 | #47 |
| Revenue (latest FY) | $3.71B | - |
| Net income (latest FY) | $313.75M | - |
| Net margin | 8.4% | - |
| P/E (trailing FY) | 123.1 | - |
| SEC filings | 1,651 | 947 |
Novartis AG is 7.3x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($283.13 B vs $38.62 B).
Full pages: ALNYLAM PHARMACEUTICALS, INC. and Novartis AG, or browse the full rankings.